IMMUNORX PHARMA
ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and Crohn’s disease. The company's antibody targets a new critical target in chronic inflammation and auto-immunity which was originally discovered by Dr. Tessier in Canada.
IMMUNORX PHARMA
Industry:
Health Care Medical Medical Device
Founded:
2020-01-01
Status:
Active
Total Funding:
2.67 M USD
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Equinox
Equinox is a developer of a medical technology in revolutionizing the treatment of glaucoma and other progressive eye diseases.
InTouch Health
InTouch Health is the leader in Acute Care Telemedicine solutions.
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Portal Instruments
Portal Instruments is an early stage company that offers medical device.
Summit BHC
Summit Behavioral Healthcare is an Atlanta-based provider of addiction treatment and behavioral health services.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
More informations about "ImmunoRx Pharma"
ImmunoRx Pharma - Crunchbase Company Profile
ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and …See details»
ImmunoRx Pharma - Funding, Financials, Valuation & Investors
ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases.See details»
ImmunoRx Pharma 2025 Company Profile: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for ImmunoRx Pharma. Use the PitchBook Platform to explore the full profile.See details»
TVM Life Science Innovation II SCSp Announces Investment in …
Jan 19, 2021 ImmunoRx Pharma, Inc. plans to begin clinical development by the end of 2022. Once cleared for clinical development by regulatory authorities, the ImmunoRx Pharma, Inc. …See details»
ImmunoRx Pharma Inc. - TVM Capital Life Science …
ImmunoRx Pharma, Inc. plans to develop a first-in-class antibody, to proof-of-concept, with the potential to treat certain types of chronic inflammatory diseases, including ulcerative colitis, rheumatoid arthritis and Crohn’s disease. This …See details»
Immunorx Pharma, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Immunorx Pharma, Inc. of Wilmington, DE. Get the latest business insights from Dun & Bradstreet.See details»
ImmunoRx - LinkedIn
ImmunoRx | 335 followers on LinkedIn. A subsidiary of Voirx, Focuses on manufacturing cancer oncolytics and immunotherapeutic productsSee details»
Immunorx Pharma, Inc. | MedPath
First Posted Date 2024-04-10 Last Posted Date 2025-03-26 Lead Sponsor ImmunoRx Pharma Inc. Target Recruit Count 83 Registration Number NCT06356259See details»
ImmunoRx Pharma, Inc. - Drug pipelines, Patents, Clinical trials
Explore ImmunoRx Pharma, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 2 news, Technology Platform:Biological products, Drug ...See details»
IMMUNORX PHARMA, INC. Top 13F Holdings - WhaleWisdom.com
Detailed Profile of IMMUNORX PHARMA, INC. portfolio of holdings. SEC Filings include 13F quarterly reports, 13D/G events and more.See details»
IRX-010 by ImmunoRx Pharma for Inflammation: Likelihood of …
Jan 6, 2025 IRX-010 is under clinical development by ImmunoRx Pharma and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase …See details»
ImmunoRx Pharma - Contacts, Employees, Board Members
ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases.See details»
ImmunoRx Pharma | VentureRadar
RDP Pharma (RDP) is a privately held biotech, dedicated to the vision that their products will deliver valuable medicines to patients in need. The company's projects include: Next …See details»
ImmunoRx Pharma - Products, Competitors, Financials, Employees ...
About ImmunoRx Pharma ImmunoRx Pharma develops the first-in-class antibody, to proof-of-concept, with the potential to treat certain types of chronic inflammatory diseases, including …See details»
IRX-010 - Drug Targets, Indications, Patents - Synapse
Mar 28, 2025 IRX-010, Initially developed by ImmunoRx Pharma, Inc., Now, its global highest R&D status is Discontinued.See details»
TVM Capital Life Science acquires ImmunoRx Pharma - Crunchbase
Jan 19, 2021 ImmunoRx Pharma ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases.See details»
ImmunoRx Pharma, Inc.: Drug pipelines, Patents, Clinical trials
Explore ImmunoRx Pharma, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
IRX 010 - AdisInsight
Apr 23, 2024 IRX 010 is intravenous drug candidate being developed by ImmunoRx Pharma for undisclosed indication. Clinical development is underway in Netherlands.See details»
ImmunoRx Pharma - VentureRadar
The venture focuses on accurately replicating biological processes to simulate clinical trial outcomes without the need for a client to step into a lab. The venture has two validated …See details»
ImmunoRx Pharma - Updates, News, Events, Signals & Triggers
Jan 19, 2021 ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases.See details»